RemeGen

Focus: RemeGen is a China-based biotechnology company headquartered in Yantai specializing in antibodies, fusion proteins, and bifunctional antibodies across oncology, immunology, and ophthalmology. The company operates a diversified pipeline with 20 active clinical programs spanning Phase 1 through Phase 3 development.

Oncology Immunology Ophthalmology Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About RemeGen

AI assessmentNot Hiring

No open roles listed right now. Follow RemeGen to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Disitamab Vedotin

HER2

N/A

Clinical Trials (1)

NCT05649163Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

N/A

Help build intelligence for RemeGen

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Robust clinical pipeline with 7 Phase 3 programs providing multiple near-term catalysts and career visibility in drug development
Deep expertise in differentiated modalities (ADCs, bifunctional antibodies, fusion proteins) offering specialization opportunity in high-value therapeutic areas
Diversified therapeutic portfolio spanning oncology, immunology, ophthalmology, neurology, and nephrology reduces single-indication risk and expands career trajectory options

Watch Out For

No current active job openings and limited hiring activity signal contraction or consolidation phase, reducing near-term employment opportunity
Lack of disclosed financial data (revenue, R&D spend, cash position) creates uncertainty about runway, investment capacity, and long-term stability

Generated by Claude from RemeGen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Disitamab Vedotin and Cisplatin

Uterine Cervical Neoplasms

N/A

Clinical Trials (1)

NCT06558682Neoadjuvant Therapy in Cervical Cancer

N/A

Disitamab vedotin

Solid Tumor

Phase 1

Clinical Trials (1)

NCT05940896RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

Phase 1

RC48-ADC

Solid Tumors

Phase 1

Clinical Trials (1)

NCT02881190Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors

Phase 1

RC198 Injection

Melanoma

Phase 1

Clinical Trials (1)

NCT05867303A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Phase 1

RC48-ADC

Gastric Cancer

Phase 1

Clinical Trials (1)

NCT05514158To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)

Phase 1

RC98

Solid Tumors

Phase 1

Clinical Trials (1)

NCT04190823A Study of RC98 in Subjects With Advanced Malignant Solid Tumors

Phase 1

Tai Ai

Healthy

Phase 1

Clinical Trials (1)

NCT04235933A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects

Phase 1

RC148 plus Carboplatin and Paclitaxel/pemetrexed

Non-Small Cell Lung Cancer

Phase 1

Clinical Trials (1)

NCT06883630A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

Phase 1

RC118 for injection

Unresectable Solid Tumor

Phase 1

Clinical Trials (1)

NCT04914117A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours

Phase 1

RC28-E

Neovascular Age-related Macular Degeneration

Phase 1

Clinical Trials (1)

NCT03777254Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration

Phase 1

RC48-ADC

Solid Tumors

Phase 1

Clinical Trials (1)

NCT02881138A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors

Phase 1

RC48-ADC in combinaton with JS001

HER2-Positive Solid Tumors

Phase 1

Clinical Trials (1)

NCT04280341JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors

Phase 1

Telitacicept

Systemic Lupus Erythematosus

Phase 1

Clinical Trials (1)

NCT05687526A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus

Phase 1

Telitacicept Pre-filled Injection 80mg

Healthy

Phase 1

Clinical Trials (1)

NCT06549959A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects

Phase 1

Telitacicept

Systemic Lupus Erythematosus

Phase 1

Clinical Trials (1)

NCT05247203Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus

Phase 1

RC108

Solid Tumor

Phase 1

Clinical Trials (1)

NCT04617314A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors

Phase 1

RC108

NSCLC

Phase 1/2

Clinical Trials (1)

NCT05821933RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

Phase 1/2

RC118-ADC

Advanced Solid Tumor

Phase 1/2

Clinical Trials (1)

NCT05205850A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Phase 1/2

RC88

Solid Tumor

Phase 1/2

Clinical Trials (1)

NCT04175847A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors

Phase 1/2

RC118

Advanced Solid Tumor

Phase 1/2

Clinical Trials (1)

NCT06038396A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors

Phase 1/2

RC148 Monotherapy

Solid Tumor

Phase 1/2

Clinical Trials (1)

NCT06016062A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Phase 1/2

RC48-ADC 1.5 mg/kg

Advanced Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT03052634A Study of RC48-ADC in Subjects With Advanced Breast Cancer

Phase 1/2

Disitamab Vedotin for injection

High-risk Non-muscle Invasive Bladder Cancer

Phase 1/2

Clinical Trials (1)

NCT06378242To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

Phase 1/2

RC48-ADC

Non-small Cell Lung Cancer

Phase 1/2

Clinical Trials (1)

NCT05745740A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Phase 1/2

RC48

Non Small Cell Lung Cancer

Phase 1/2

Clinical Trials (1)

NCT04311034A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer

Phase 1/2

intravitreal injection of RC28-E 0.5mg

Wet Age-Related Macular Degeneration

Phase 1/2

Clinical Trials (1)

NCT04270669Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration

Phase 1/2

RC288 For Injection

Solid Tumors

Phase 1/2

Clinical Trials (1)

NCT07537881A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors

Phase 1/2

RC88

Advanced Solid Tumours

Phase 1/2

Clinical Trials (1)

NCT05508334A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours

Phase 1/2

RC278

Solid Tumors

Phase 1/2

Clinical Trials (1)

NCT07105215A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors

Phase 1/2

RC88

Advanced Solid Tumours

Phase 1/2

Clinical Trials (1)

NCT05804526A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

Phase 1/2

RC48-ADC

Melanoma, Stage II

Phase 2

Clinical Trials (1)

NCT05135715A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Phase 2

RC18 160mg

Primary IgA Nephropathy

Phase 2

Clinical Trials (1)

NCT04291781A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy

Phase 2

Telitacicept 160mg

IgA Nephropathy

Phase 2

Clinical Trials (1)

NCT04905212A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

Phase 2

RC48-ADC

Urothelial Carcinoma

Phase 2

Clinical Trials (1)

NCT03507166A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

Phase 2

Disitamab Vedotin

Cervical Cancer

Phase 2

Clinical Trials (1)

NCT06155396A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Phase 2

Disitamab Vedotin Injection

Castration-resistant Prostate Cancer

Phase 2

Clinical Trials (1)

NCT06227156Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

Phase 2

RC108

Non-Small Cell Lung Cancer

Phase 2

Clinical Trials (1)

NCT06962865A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Phase 2

RC48-ADC

Urothelial Carcinoma

Phase 2

Clinical Trials (1)

NCT04073602A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer

Phase 2

Telitacicept 240 mg

Lupus Nephritis

Phase 2

Clinical Trials (1)

NCT05680480A Study of Telitacicept in Lupus Nephritis

Phase 2

RC48

Non-Muscle Invasive Bladder Cancer

Phase 2

Clinical Trials (1)

NCT05957757RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

Phase 2

RC48-ADC

Gastric Cancer

Phase 2

Clinical Trials (1)

NCT03556345A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2

Phase 2

Disitamab Vedotin Injection （18 weeks）

Breast Cancer

Phase 2

Clinical Trials (1)

NCT06227117Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Phase 2

RC18 160mg

Multiple Sclerosis, Relapsing-Remitting

Phase 2

Clinical Trials (1)

NCT04625153RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial

Phase 2

Disitamab Vedotin

Breast Cancer

Phase 2

Clinical Trials (1)

NCT06642545Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Phase 2

Tislelizumab

HER2-positive or Mutated Advanced Colorectal Cancer

Phase 2

Clinical Trials (1)

NCT05350917Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy

Phase 2

RC48-ADC

Non-muscle Invasive Bladder Cancer

Phase 2

Clinical Trials (1)

NCT05996952RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer

Phase 2

RC18 160mg

Systemic Myasthenia Gravis

Phase 2

Clinical Trials (1)

NCT04302103A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis

Phase 2

Placebo plus MTX

Moderate and Severe Rheumatoid Arthritis

Phase 2

Clinical Trials (1)

NCT02882087A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

Phase 2

RC48-ADC in Combination with gemcitabine

NMIBC

Phase 2

Clinical Trials (1)

NCT05943379RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

Phase 2